Quote:

---

But is that survival rate for Troldelvy based on its use as first line treatment, or was that result also after multiple failed treatments?

---

he FDA approved Trodelvy based on the results of a clinical trial of 108 patients with metastatic triple-negative breast cancer who had received at least two prior treatments for metastatic disease.